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Synthetic polymer leaflets in prosthetic cardiac valves hold the potential to reduce 
calcification and thrombus, while improving blood flow, durability, and device economics.  A 
recently developed siloxane poly(urethane-urea) (LifePolymer™, LP) exhibits properties 
essential for heart valve leaflets, including low dynamic modulus, high tensile strength, 
minimal creep, and excellent biostability.  LP properties result from carefully designed 
“linked co-macrodiol” chemistry that maximizes silicone content and virtual crosslinks 
between soft and hard phases.  Characterization of multiple commercial batches demonstrates 
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a robust synthesis process with minimal variation.  Extensive ISO 10993-based 
biocompatibility testing resulted in no observable toxicity or other adverse reactions.  An ex 
vivo AV shunt thrombogenicity investigation revealed nearly undetectable levels of platelet 
attachment and thrombus formation on LP surfaces.  Chronic ovine implantation of prototype 
heart valves with LP leaflets showed no differences in thrombogenicity or systemic tissue 
response when compared to a clinically standard tissue-based valve.  Toxicological risk 
assessment, based on extractables and leachables analysis of LP-based heart valves, 
confirmed minimal toxicological risk.  Lastly, 24-week, strain-accelerated in vivo LP 
biostability testing confirmed previous favorable in vitro biostability findings.  These studies 
demonstrate that this newly developed elastomer exhibits ideal biomaterial properties for the 
flexible leaflets of a totally synthetic heart valve replacement. 
 
1. Introduction 
As (AB)n-type segmented block copolymers, polyurethanes (PUs) are comprised of three 
primary building block chemistries in tailored covalently linked sequences to yield polymer 
chain segments.  These PU building block chemistries generally are: 1) macrodiol or polyol, 
2) diisocyanate, and 3) chain extender.  Myriad chemical combinations of these three 
components, each with several different chemistry possibilities, result in a substantial array of 
PUs with interesting ranges of useful properties.[1,2] Tailored PU mechanical and chemical 
properties derive from their molecular-level construction that yield distinct hard segments and 
soft segments which self-organize based on intermolecular forces (e.g., chain hydrogen 
bonding), segment association, and relative immiscibility to create microphase-separated 
polymer solids.  PU microphase separation unique to each selected segment chemistry has 
long been proposed as essential to their compelling mechanical (e.g., tensile strength, elastic 
properties, hardness) and chemical behaviors (e.g., gas/water permeability, hydrolytic stability, 
biocompatibility).[1-3] 
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Biomedical PUs enjoy a substantial history of materials development and track records of 
success across a diverse palette of medical products.[4]  Numerous academic and clinical 
medical implant development experiences have demonstrated how PU chemistry is related to 
both its biocompatibility and biostability.  Adoption and re-purposing of early PU materials 
from other commercial applications for medical device use resulted in many successes and a 
small number of notable performance challenges.  Specifically, commercialized 
polyetherurethane-based pacemaker lead insulation coatings and breast implant porous 
coatings both exhibited device-associated failures attributed to polymer degradation 
mechanisms catalyzed under physiological conditions.[5]  Oxidative degradation of the 
polyether soft segment associated with PU elastomeric properties was considered deleterious 
to these early implanted PUs.[6,7]  This link between PU segment chemistry and resulting in 
vivo PU implant performance served to distinguish the unique in vivo environmental demands 
for biomedical PUs, and motivated extensive and continuing efforts to improve PU 
biostability for long-term implantation.[4] 
One approach to reducing polyether-based PU oxidative degradation susceptibility has 
exploited new polyether polyol building blocks with fewer ether groups, such as 
poly(hexamethylene oxide) (PHMO), which has been shown to improve in vivo stability and, 
importantly, serve also to improve chemical compatibility of apolar siloxane (e.g., 
polydimethylsiloxane oligomers, PDMS) soft segment building blocks.[4, 8-12]  Substantial 
recent developments, including intelligent selection of PDMS terminal functional groups and 
the use of a second macrodiol as a segment compatibilizer, have enabled controlled phase 
mixing between PU soft and hard segments with superior mechanical properties and enhanced 
PDMS-PU in vitro hydrolytic resistance and in vivo biostability.[4, 13-16] Latest generation 
commercially available PDMS-based biomedical PUs utilize a two-step bulk polymerization 
process, allowing scalable mass production without metal catalysts and improved mechanical 
characteristics and biostability suitable for medical devices (e.g., Elast-Eon 2A®, or E2A, 
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AorTech Biomaterials, UK).[17,18]  E2A‟s superior biostability versus conventional polyether 
PU Pellethane® 2363-80A has been shown in numerous ovine subcutaneous implantation 
studies.[16, 19-22]  A translational success story, Abbott‟s E2A-based Optim® cardiac lead 
insulation has been clinically implanted since 2006, with over 6 million patients benefiting 
worldwide.[23]   
Despite their clinical success, recent in vitro studies using Arrhenius-accelerated 
hydrolysis have raised concerns over long-term siloxane-based PU biostability.[24-27]  A 
recognized primary limitation of Arrhenius-type, temperature accelerated, in vitro degradation 
models is the high and sustained testing temperatures producing PU microstructural and 
morphological changes not observed in vivo.[28]  Most significantly, temperature-accelerated 
in vitro PU degradation results do not correlate with the very minimal changes seen in 5-year 
and 8 year clinical explants of Optim® (E2A) pacemaker leads.[29,30]  An actively monitored 
registry study of the first commercially released Optim cardiac leads, encompassing 14,500 
devices over 73,000 patient years, confirms Optim‟s in vivo stability with an outstanding all-
cause device survival rate of 98.3% after more than 12 years of implantation.[23]  Given 
significant ambiguities in accelerated in vitro testing to predict actual PU in vivo stability, 
future focus should be on improving these in vitro models and validation against long-term 
implant studies.  Establishing strong in vitro-in vivo correlations is required to confidently 
accelerate further development of siloxane-based PUs central to several important medical 
device classes in clinical use, including prosthetic heart valves. 
Prosthetic heart valves are well-established, lifesaving medical devices.  While 
complications such as thrombosis and calcification do occur, the rates are relatively low and 
valve performance and longevity is considered acceptable.  The majority of heart valves 
implanted today feature leaflets made with fixed exogenous cardiac tissue, i.e. bovine 
pericardium or porcine valve leaflet.  A smaller fraction of implanted heart valves utilize a 
rigid mechanical design featuring one or more pivoting carbon discs/leaflets.  Carbon valves 
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are acknowledged to be extremely durable, however, due to the non-physiological flow and 
material surface chemistry, strong anticoagulation therapy is required and hemolysis is a 
concern.  Tissue valves require only mild anticoagulation therapy, demonstrate good 
longevity, and can be delivered by a minimally invasive catheter, however calcification 
complications remain a concern.   
Because polymer properties can be carefully tuned and controlled, the possibility of using 
polymeric leaflets in prosthetic heart valves has been carefully explored by multiple 
organizations.  In addition to physical properties, the geometry of polymer valve leaflets can 
be intentionally designed to ensure ideal physiological function, approaching that of native 
leaflets.  Therefore, molded or solution processed polymer heart leaflets offer the potential for 
low cost, highly-controlled, physiologic, minimally invasive, prosthetic valves with excellent 
hemodynamics.  Historically, many polymers have been explored as leaflet materials, 
including silicone rubber, polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE), 
polyvinylalcohol (PVA), poly(styrene-isobutylene-styrene) (SIBS), and an array of 
polyurethanes.[31]  However, to date, no prosthetic valve with polymeric leaflets has achieved 
commercial success.  Familiar clinical issues such as hemodynamics, thrombosis, and 
calcification, as well as in vivo degradation have been the primary challenges. 
New PDMS-PU chemistries continue to be reported, seeking to improve in vivo 
biomaterials performance using PU structure-property relationships.[4]  Arguably, siloxane-
containing PUs exhibit the best biostability and biocompatibility to date, but frequently lack 
state of the art mechanical properties.  Application-specific properties for medical devices 
require control of specific PU mechanical properties together with robust, reliable biostability 
under implant conditions.  Synthetic heart valve leaflets, for example, require high tensile and 
tear strengths, high resistance to creep deformation, and specific dynamic moduli.  PUs were 
not capable of delivering these requisite properties until siloxane-based PUs with controlled 
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microphase morphologies using new molecular and segmental architectures were produced, 
surpassing known mechanical properties for E2A.[32-35] 
This study reports chemical, in vitro, and in vivo analysis of a first-in-class biomedical 
grade siloxane-based poly(urethane-urea) (SiPUU) (LifePolymer®, LP, Foldax, USA) 
specifically developed for synthetic leaflets in a prosthetic heart valve (Tria™, Foldax, USA).  
After significant development efforts, which were thoroughly described in a series of 
publications, LP met property goals established to ensure proper and safe mechanical function 
of Tria valve leaflets, including ≥30 MPa UTS, ≥500% elongation, ≥50 N/mm tear strength, 
≥200 J m-2 tear energy threshold, 25-35 MPa dynamic modulus, creep rate < E2A, and 
biostability ≥ E2A.[32,35,36]  LP‟s published synthesis and chemical design exploits 5 distinct 
pre-polymer building blocks, including a diamine chain extender and siloxane-containing 
macrodiol and hard segment components, facilitating co-macrodiol soft segment interactions 
with hard segments using both carbamate and urea chemistry.[32-35]  LP soft segments are 
based on a 20:80 (w/w) mixture of 4,4‟-methylenediphenyl diisocyanate (MDI) linked PHMO 
and telechelic α,ω-bis(6-hydroxyethoxypropyl)-PDMS.  LP hard segments represent nearly 
45% (w/w) of total mass, comprising MDI and a mixture of 1,2-ethylenediamine (EDA) and 
1,3-bis (4-hydroxybutyl)-1,1,3,3-tetramethyldisiloxane (BHTD).[32]  The creative urethane-
urea polymer construction distinguishes this siloxane PU from E2A and another analogous 
commercial biomedical siloxane-based PU, PurSil35 (DSM Biomedical, NL), that each 
contain 4 linking components, but, notably, lack BHTD and the urea linking chemistry that 
results from the inclusion of EDA.  Innovative multi-step, scalable polymer processing yields 
~50% PU siloxane content, a silicone-rich PU surface, and high levels of hydrogen-bonded 
inter-segment interactions between soft and hard segment phases.[32,34]  LP‟s molecular design 
is responsible for the demonstrated superior mechanical features and biostability necessary for 
use as a synthetic prosthetic heart valves leaflet.[32-35]  Building on the previously published 
exploration and characterization data, this study provides a wide range of additional in vitro 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved 
and in vivo evidence supporting LP in this promising cardiovascular device application.  
These data include further material characterization, batch-to-batch consistency, ISO10993 
biocompatibility, ex vivo thrombogenicity, extractables and leachables toxicological 
assessment, chronic ovine valve implants, and accelerated in vivo biostability.   
 
 
2. Results 
2.1. Characterization of production-scale SiPUU 
An initial 14 LP synthetic batches have been completed commercially.  Each was 
thoroughly characterized to ensure a consistent, high quality polymer with specifications 
necessary for valve leaflet production.  Data from these batches are presented in Table 1 and 
examples of the raw data are included in the Supporting Information.  While many 
specifications remain proprietary, the inter-batch production data demonstrate robust 
consistency.  Standard deviations of the polymer mechanical properties are all within 6% of 
the averages and Tg standard deviations are <3 °C.  Even polymer molecular weight GPC data, 
typically acknowledged to produce method-based variability +/-10%, is within 16% of the 
mean value.  Notably, molecular weight, ultimate tensile strength, and elongation averages are 
significantly above those reported for earlier SiPUU lab-scale development, while PDI 
remains consistent, indicating an improvement in process capability at the larger scale.[32]  
Dynamic modulus, a critical parameter to ensure proper leaflet movement, blood flow, and 
overall valve sealing, is remarkably consistent and well within the 25-35 MPa target range 
identified during material development and valve leaflet specifications.  Tear energy threshold, 
defined as the energy level that can be cyclically applied to a leaflet without propagation of a 
cut/tear, easily exceeds the minimum design requirement of 200 J m-2 and provides a >2x 
margin of safety during aortic valve function.[37] 
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2.2. Aortic Valve Fabrication 
The Foldax Tria™ Aortic Valve design (Figure 1) is a 100% synthetic polymer prosthetic 
aortic heart valve repeatedly fabricated for pre-clinical and biocompatibility testing.   The 
valves consist of LP leaflets solution-cast onto a radio-visible PEEK stent and a PTFE felt 
sewing ring secured with polyester suture.  Sterilization was achieved by standard ethylene 
oxide methods.  The Tria valves fabricated for this study underwent all manufacturing 
processes/controls and met all visual, mechanical, and dimensional specifications necessary 
for human use.   
 
2.3. Biocompatibility 
Because a complete medical device best represents patient exposure, biocompatibility 
testing described in this study was performed on a complete, sterilized Tria heart valve with 
an approximate composition of 40wt% LP, 40wt% PEEK, and 20wt% PTFE.  
Biocompatibility assessments were completed in compliance with ISO 10993 standards and 
GLP regulations.  A summary of each test result is provided in Table 2.  All biocompatibility 
testing met the relevant criteria, identifying no significant risk of toxicity or tissue injury.  
Successful ISO 10993 biocompatibility results, such as those detailed for the Tria valve with 
LP leaflets, are necessary to ensure patient safety and secure regulatory approval of 
implantable medical devices worldwide. 
 
2.4. Toxicological risk assessment from exhaustive extraction and leachables analysis of 
Tria valves 
GC-MS and LC-MS analysis of exhaustive Tria valve extracts (polar, semi-polar, apolar) 
identified low levels of 37 unique compounds and 24 groups of related compounds (Table 3).  
Identical analysis of PBS and ethanol/water simulated-use leachables solutions identified low 
levels of 33 unique compounds and 11 groups of related compounds (Table 3).  Examples of 
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compound groups included ethylene glycols, fatty alcohols, siloxane cyclics, siloxane 
oligomers, DMAc-related compounds, MDI-related oligomers, and MDI-diol-siloxane related 
oligomers.  The identification of very low levels of extractable compounds is typical, even for 
implant-grade polymers, due to the high sensitivity of these analytical methods. 
As an outcome of the comprehensive toxicological assessment, Margin of Safety (MOS) 
values were calculated for each of the unique compounds and related compound groups 
identified by GC-MS and LC-MS.  MOS values ≥1 indicate a minimal and acceptable risk of 
toxicity when the device is used as intended.  MOS values <1 require additional consideration 
to make a final toxicity determination.  Minimal toxicity (MOS≥1) was confirmed for all 
compounds leachable under simulated-use conditions and those compounds identified with 
polar and semi-polar solvents under aggressive, exhaustive extraction conditions.  Only under 
the non-physiological conditions of an exhaustive hexane solvent extraction at 50 C for 72 
hours were compounds identified with a MOS less than 1.0, ranging between 0.5 and 0.9.   
ICP-MS identified eight metals, Mg, Al, B, Na, Si, K, Ca, and Ba, found in quantities of 
at least 1µg/device in exhaustive water extractions, PBS leachables analysis, and 
ethanol/water leachables analysis.  The MOS of these elements was remarkably high, ranging 
from 79 to 501,400.  As a result, no toxicity concerns were related to extractable or leachable 
elements. 
All available data were then considered to assess overall toxicology risk for the Tria 
valve with LP leaflets.  Acknowledging the successful completion of ISO10993 
biocompatibility testing (including acute systemic toxicity and genotoxicity), a minimal 
toxicity assessment from the simulated use leachables analysis, and the understanding that the 
MOS from exhaustive extractions significantly overestimates potential biological exposure, 
the Tria valve with its three LP leaflets was concluded to represent minimal toxicity risk. 
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2.5. Subchronic preclinical histological evaluation of implant Tria valves with LP leaflets 
in sheep 
Eight (8) sterilized Tria valves (23mm) with LP leaflets were successfully implanted in 
the aorta of 8 sheep for a 140 day period.  Human Carpentier-Edwards Perimount™ aortic 
valves (model 2900-25mm) were implanted in 2 sheep as controls.   
No significant health problems were observed for the 10 valve-implanted sheep during 
the course of the 140 day study.  Clinical chemistry data identified no significant trends.  All 
animals gained weight throughout the study.  No mineralization, hemorrhage, or valve surface 
thrombus was observed on either LP or control valves.  Additionally both valve types 
demonstrated only minimal inflammation adjacent to the sutures and the aorta were found to 
be patent with no thrombi. The LP leaflets supported no fibrous tissue (pannus) or 
endothelialization.  The control leaflets demonstrated a mild amount of fibrous tissue (pannus) 
coverage, but no endothelialization was observed.  Overall, the assessed gross and 
microscopic histopathological parameters (Figure 2) of the Tria valve and adjacent tissues 
were similar or superior for the LP test articles compared to the control articles, had minimal 
severity, and did not create any clinically significant findings or safety concerns in this animal 
model.   
Histopathological assessment of organs and tissue not in close proximity to the valves 
(kidneys, lungs, liver, gallbladder, spleen, lymph nodes, and brain) did not identify any 
notable findings unique to the Tria valve. 
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2.6. Ex vivo non-human primate AV shunt thrombogenicity 
The ex vivo, non-human primate (NHP) AV shunt method previously described by 
Harker and Hanson was successfully employed to evaluate thrombogenicity of LP grafts 
(n=6) and ePTFE control grafts (n=5) (Figure 3).[38]  Overall platelet deposition on LP grafts 
was minimal (<0.08x109 platelets) for the entire 60 minute study period (Figure 4). This low 
platelet deposition is an order of magnitude below historical published results on ePTFE 
grafts with clopidogrel (20 mg kg-1) and aspirin (10 mg kg-1) which had 2.0±0.4x109 platelets 
after 60 minutes.[39]  A statistical comparison of LP and ePTFE graft platelet deposition 
confirmed that ePTFE grafts underwent significantly (p < 0.05 in t-test) higher platelet 
attachment at 30, 45, and 60 minutes.  
Fibrin accumulation on 4 of 6 LP grafts was sufficiently low to be below the gamma 
counter detection limit.  The average amount of fibrin present on the LP devices was 
0.003±0.007 mg, orders of magnitude lower than the average ePTFE device fibrin deposition 
of 0.844±1.156 mg.  A single ePTFE replicate exhibited >8x the fibrin accumulation (2.897 
mg) of the average of the other four (0.331 mg).  No justification for this outlying data point 
could be identified.  The resulting standard deviation of the ePTFE fibrin data with this outlier 
was high and statistically significant differences vs LP were not identified (t-test, p = 0.179).  
Removal of this outlier from the ePTFE dataset results in a statistically significant difference 
(p = 0.027) between the LP and ePTFE samples. 
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2.7. In vivo biostability from pre-strained LP films in rabbit subcutaneous implants 
Pre-strained LP and control polyurethane (Pellethane 80A and Pellethane 55D) 
dumbbells were successfully implanted subcutaneously above the dorsal muscle of eight (8) 
rabbits for 3-6 months.  Sixteen (16) of each sample type were implanted.  Of the 48 
implanted samples, surgical complications or infection required 10 samples (3 LP and 7 
controls) to be explanted and removed from the study within 30 days of implant.   No other 
implant-related health issues were noted during the study. 
Figure 5 details the results of visual examination scoring, which attempts to classify the 
extent of any visible degradation.  The 6 month rabbit model was successful in causing 
significant degradation (score of 6) in the positive control samples.  A moderate amount of 
surface degradation was even identified in the negative controls (score of 4).  Note that the 
Pellethane 55D Negative Control is a biomaterial successfully implanted clinically for 
decades, but has been shown to demonstrate mild degradation in vivo and in accelerated in 
vitro testing.[30,40]  Our control results confirm that the 150% strain level in this rabbit model 
is a strong accelerator of PU degradation.  Even with this level of acceleration, the LP 
samples showed no visual signs of degradation (score of 1).   
Figure 6 provides typical FE-SEM images and general observations for the LP and 
control groups after 6 months.  Note that due to the challenges associated with assessing 
transparent sample surfaces with light microscopy, FE-SEM assessments may deviate 
somewhat from visual evaluation results of the same samples.  The positive controls 
(Pellethane 80A) show significant surface pits, cracking, and complete separation of the 
central region of one sample.  The negative controls (Pellethane 55D) showed minor surface 
pitting and cracking at both time points.  Note that the FE-SEM imaging identified less pitting 
and shallow cracking in the negative control than the visual examination.  The LP test articles 
showed no signs of pitting, cracking, or any other types of degradation even at 6 months.   
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These study data show that the LP material is highly biostable, even in an in vivo model 
accelerated by strains that are >10X the expected strain in a valve leaflet.  Additionally, FE-
SEM-EDAX analysis found no evidence of calcium deposition on the LP test article at either 
3 or 6 month time points (data not shown).   
 
3. Discussion 
A completely synthetic and clinically reliable heart valve prosthesis has been elusive, 
requiring highly complex combinations of valve design, biomaterials combinations, 
manufacturing constraints, implant tools, and surgical techniques.  The newly designed Tria 
aortic replacement valve contains elastomeric polymer leaflets of a new synthetic siloxane 
poly(urethane urea) (SiPUU) commercialized as LifePolymer™ (LP, Foldax, USA).  A series 
of previous publications has extensively described LP‟s synthetic chemistry, cast bulk film 
microstructure, silicon surface enrichment, unique polymer processing, and extensive physical 
properties relevant to synthetic heart valve application.[32-35]  Replacement of traditional 
xenogeneic pericardial tissue leaflets with high performance SiPUU provides the advantages 
of a highly controlled leaflet design, ideal and tailored mechanical properties, a robust supply 
chain, and lower manufacturing costs.  Nonetheless, translation, clinical testing and 
commercialization of any replacement heart valve requires development and testing according 
to a number of guidance and standards documents, including ISO 10993 “Biological 
Evaluation of Medical Devices”, ISO 5840-1 “Cardiac valve prostheses: general 
requirements”, and ISO 5840-2 “Cardiac valve prostheses: surgically implanted heart valve 
substitutes”.  Results from a series of studies intended to validate the biocompatibility, safety, 
and stability of the LP leaflet material and the Tria aortic valve prosthesis are aligned with 
these guidances.  Together with the earlier reported work on this new SiPUU copolymer, an 
exhaustive data set now confirms LP‟s suitability for use as a leaflet in a replacement heart 
valve. [32-35]  
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Many important chemical, thermal, and physical properties of LP made at the laboratory 
scale have been described during the LP biomaterial‟s early development. [32-35]  These include 
important benchmarks for LP‟s solvent processable mechanical properties (elasticity, tensile 
strength, tear strength, creep) attributed to unique co-macrodiol chain-extended segmental 
interactions with new hard segments also containing siloxane chemistry, cast surfaces 
consistently and substantially enriched in siloxane low energy blocks, and both carbamate and 
urea linkages imparting stability and regular hydrogen bonding.[33,34]  Extending this bench 
synthesis to the first stages of device translation, multiple LP batches commercially 
synthesized at scale demonstrate a high level of process control.   Modest enhancements in 
molecular weight, ultimate tensile strength, and elongation over previously reported lab-scale 
properties further indicate improvements in process capability at the larger scale. 
The ISO 10993 biological evaluation standards are adopted globally as part of a risk 
management process for verifying the biocompatibility of finished medical devices, including 
heart valves.  Because a heart valve remains in long term blood and tissue contact, ISO 
10993-1 requires the most rigorous battery of tests, including cytotoxicity, intracutaneous 
reactivity, material mediated pyrogenicity, systemic toxicity, implantation effects, 
hemocompatibility, and genotoxicity.  A carcinogenicity assessment is also expected if the 
device contains any known mutagens, carcinogens, or reproductive toxins.   
The Tria valve with LP leaflets passed all standard biocompatibility testing, identifying 
LP in this context as non-cytotoxic, a non-irritant, a non-sensitizer, non-pyrogenic, non-
genotoxic, non-clastogenic, and producing no acute systemic toxicity (Table 2).  Longer term 
subchronic toxicity testing in an ovine model identified no risk of localized or systemic 
toxicity.  The Tria valve materials were also determined to be non-genotoxic by both standard 
AMES and Mouse Lymphoma methods.  These results and the absence of any known 
genotoxic or carcinogenic compounds in the LP formulation, justified not performing a 
carcinogenicity test, in agreement with ISO 10993-1 guidelines.   
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As per ISO 10993-4, the blood compatibility of any heart valve must be assessed with 
both hemolysis and in vivo/ex vivo thrombosis studies.  As shown in Table 2, the Tria valve 
materials were non-hemolyzing and demonstrating acceptably low rates of coagulation with 
PTT and complement activation in vitro studies.  The ex vivo thrombosis assay using the LP-
based A-V NHP shunt (Figure 4) further supported low coagulation activation by LP, 
producing nearly undetectable levels of platelet attachment and fibrin deposition in situ, both 
key markers of thrombosis.  Essential for any heart valve leaflet material, the Tria valve and 
LP leaflets have both shown exceptional hemocompatibility in two different large animal 
models (see Figures 2 and 4).  This is attributed to high, non-stoichiometric levels of siloxane 
at the LP leaflet surface, known to favor hemocompatibility.[32]   
A substantial fraction of adverse effects from implanted medical devices are attributed to 
the unintended release of compounds or elements.[40]  Polymeric biomaterials in medical 
devices may contain extractable and potentially toxic low molecular weight species, such as 
oligomers, plasticizers, antioxidants, and processing aids.  For this reason, ISO 10993 
biocompatibility testing uses extraction techniques to isolate these compounds for biological 
assessments.  A typical complementary analytical approach described by ISO 10993-18 is the 
identification, quantification, and toxicological assessment of compounds and elements that 
are extractable under simulated-use conditions (leachables) and/or using aggressive extraction 
solvents and conditions, an “exhaustive extraction”.  In this manner, the toxicological safety 
of a device can be confirmed not only with biological testing but by state-of-the-art chemical 
analysis, such as GC-MS, LC-MS, and ICP-MS, coupled with toxicological risk assessment.   
It is important to recognize that the calculation of the MOS value is only one element of a 
toxicological assessment and it involves multiple highly conservative assumptions.  First, the 
calculation assumes that 100% of each compound extracted would be bioavailable within 24 
hours, with the same quantity released daily over the lifetime of the patient.  Under actual use 
conditions, compounds from a one-time implant are expected to leach out over weeks, months, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved 
or even years, at ever-decreasing concentrations, resulting in much lower toxicity risks.  
Additionally, under actual use conditions, many compounds identified specifically by this 
harsh apolar solvent extraction may never be released from the valve in vivo.  This can be 
seen when comparing the exhaustive extraction data with the leachables data.  Thus, the MOS 
calculations significantly overestimate potential biological exposure and toxicological risk.   
After considering the entirety of the data, including the non-toxic assessment of leachable 
compounds and element, the toxicological data from the exhaustive extractions, and the 
successful ISO 10993-1 biocompatibility test results (Table 2), including acute systemic 
toxicity, genotoxicity, and ex vivo thrombogenicity (Figure 4), the Tria valve with its three LP 
leaflets was concluded to represent minimal toxicity risk. 
Implant biocompatibility and biological safety, particularly in the context of a device 
mechanical function, as for heart valve leaflets, generally includes further assessment of 
material biostability.  ISO 10993 parts -13, -14, and -15 describe testing protocols designed to 
identify compounds produced as a result of biomaterials degradation.  In vitro studies are 
appropriate, if guidance documents or literature reports provide methodology relevant to the 
device and specific materials being considered.  Previous publications demonstrate generally 
outstanding in vitro and in vivo resistance of LP to aggressive oxidative attack.[34-35]  Many 
publications over the past 40 years use an accelerated in vivo model of polymer degradation 
for polyurethane elastomers.[20,42-43]  The 6-month rabbit implant study described accelerates 
polymer degradation in vivo by applying a constant 150% strain to the material just prior to 
subcutaneous implantation.  This level of strain is >10X the strain expected to be seen in an 
aortic valve leaflet.  Consistent with previous studies this level of applied strain elicits 
significant pitting, cracking, and material degradation in a soft polyetherurethane, such as 
Pellethane 80A (Figure 6).  Even Pellethane 55D, with successful clinical use in a variety of 
implant applications does not avoid degradation in this aggressive test (Figure 6).  By contrast, 
the strained LP samples showed no signs of degradation (e.g., pitting or cracking) even after 6 
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months of implantation under these accelerated conditions.  A similar level of biostability has 
been previously demonstrated by other siloxane-urethanes including ElastEon2A and PurSil, 
both of which have successful implant applications.[20,42]  Addition of unique new urea 
segment bonds and a siloxane-containing BHTD chain extender to enhance LP‟s mechanical 
properties required for effective valve leaflet function has not compromised its in vivo 
biostability in this accelerated assessment.   
 
4. Conclusions  
Mechanical and biological performance requirements for heart valve prosthesis leaflets 
are very demanding.  Despite the indisputable advantages of a synthetic polymer leaflet, no 
examples capable of reliable device commercial translation are known.  Substantial prior 
work highlights focused development of a siloxane polyurethane-urea biomaterial intended 
solely for use as a heart valve leaflet.[32-35]   Incorporating a high level of siloxane and 
optimized levels of urea linker chemistry, a linked co-macrodiol, and a silicone-containing 
hard segment, LP demonstrates an ideal dynamic modulus for leaflet use with a high 
mechanical strength, low creep, high tear energy threshold, and both in vitro and in vivo 
biostability.  Scaled batch-to-batch polymer production consistency, excellent ISO 10993 
biocompatibility and ex vivo thrombosis results, non-concerning toxicological risk 
assessments, successful chronic sheep implantation, and promising rabbit biostability testing 
results all confirm the biological safety of the LP biomaterial in the Tria valve device design.  
These new and promising results, together with the attractive original LP property set from 
lab-scale production, provide a diverse and substantial evidence base to proceed with the 
application of LP leaflets in a totally synthetic heart valve. 
 
5.  Experimental Methods  
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Siloxane-based poly(urethane-urea) (SiPUU) synthesis:  As previously described,LP 
SiPUU was synthesized with a multi-step synthetic process.[32]   Briefly, α,-bis(6-
hydroxyethoxypropyl)poly(dimethylsiloxane) (PDMS) was purified in a wipe film evaporator 
to remove low molecular weight cyclic siloxane compounds.  Linked PHMO was synthesized 
by reacting a 2:1 molar ratio of poly(hexamethylene oxide) (PHMO) and methylene 
diisocyanate (MDI) at 80 °C for 2 hours.  Pre-polymer was prepared by blending together 
PDMS and linked PHMO, adding MDI titrated to ensure complete reaction of the polymer, 
and stirring for 2 hours at 80 °C.  Chain extension began with the addition of 1,3-bis(4-
hydroxybutyl)-1,1,3,3-tetramethyldisiloxane (BHTD) and a 2-hour reaction period.  The final 
steps of chain extension were the dissolution of 10% w/v dimethylacetamide (DMAc) 
followed by the addition of ethylene diamine (EDA).  Chain extension was complete over 3 
hours.  The resulting approximate molar composition of LP is 50% MDI, 3% linked PHMO, 
17% PDMS, 15% BHTD, and 15% EDA.  No processing aids, antioxidants, or other additives 
are present in LP.  For testing purposes, LP films (200 µm thickness) were solution-cast from 
each batch of LP, using LP-DMAc solutions (25% w/w) applied to glass plates using a film 
casting knife, then dried at 55 C overnight.   
Molecular weight (Mw, Mn, PDI) of each batch of LP-DMAc solution was determined 
with a GPC system consisting of an HPLC pump/controller, RI detector, Styragel HT2, HT3, 
HT4, HT5 columns (Waters) at 80 °C, and a 1.0 ml min-1 flow of mobile phase (DMAc with 
50 mM LiBr).  Molecular weight values were reported relative to monodisperse polystyrene 
standards.   
Glass transition temperature (Tg) was determined with a DSC (Discovery, TA 
Instruments).  Dry film samples (3-5 mg) from each batch were equilibrated at -90 °C, then 
taken through heating (10 °C min-1), cooling (5 °C min-1), and reheating (10 °C min-1) cycles 
between -90 °C and 100 °C.  Tg values during heating, cooling, and reheating were determined. 
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Films from each LP batch were spectroscopically analyzed using a diamond ATR-FTIR 
system (iS50, ThermoFisher) over a spectral range of 525-4000 cm-1, averaging 32 scans at a 
resolution of 4 cm-1.  Each spectrum was compared to a historical reference spectrum using a 
correlation coefficient calculation (QCheck, Omnic software).  A coefficient of 1.0 indicates a 
perfect match. 
Seven (7) replicate ISO 37 type 2 dog bones were cut from a cast LP film from each 
batch.  Using a tensile testing system (Mark-10), dog bones were pulled in tension to failure at 
100 mm min-1 under ambient conditions.  Ultimate tensile strength (UTS) and elongation to 
failure were calculated for each LP batch. 
For each batch, six (6) replicate samples (10 mm x 42 mm) were punched from a LP film 
and a cut of controlled depth was made on one edge of each sample.  Using a mechanical 
tester (Electroforce 3200, Bose Instruments), these samples were subjected to a set of 50,000 
tensile fatigue cycles at 10 Hz and a maximum stress of 0.5 MPa in 37 C water.  Samples 
were then subjected to sets of 50,000 fatigue cycles at increasing stress levels in 37 C water 
until the crack/tear growth exceeded 0.1 nm cycle-1, at which point a tear energy threshold (J 
m-2) was calculated based on the energy of loading and the sample dimensions.[37]  Dynamic 
modulus (MPa) was calculated as the slope between the minimum and maximum points on 
the stress-strain curve during cyclic loading at the 0.5 MPa stress level (Figure S5).  
 
Aortic valve fabrication:  The Foldax Tria™ Aortic Valve design (Figure 1) is a 100% 
synthetic polymer prosthetic aortic heart valve with a flexible, radio-visible 
polyetheretherketone (Zeniva® PEEK, Solvay) stent and annular base with diameters between 
17 mm and 27 mm.  Three flexible LP leaflets with specifically designed thickness profiles 
were fabricated in place, on the frame, using a carefully controlled solvent casting process.  
Dipping speed and orientation, LP polymer solution (in DMAc) viscosity, environmental 
temperature and humidity, and drying parameters were critical to ensuring that cast leaflets 
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meet dimensional specifications with micron-level precision.  After polymer film casting, a 
mechanical trimming step was performed to finalize LP leaflet dimensions.  A PTFE felt 
sewing ring was secured onto the annular PEEK valve base using a polyester suture running 
through a series of regularly spaced holes in the base outer annulus.  Sterilization was 
achieved by standard ethylene oxide methods. 
 
Biocompatibility assessments:  A series of ISO 10993-based biocompatibility tests was 
performed on sterilized Tria Aortic Valves with LP leaflets.  A complete Tria heart valve 
consists of  LP leaflets (~40% w/w), a rigid frame made of implant grade PEEK (~40% w/w), 
a sewing ring (~20% w/w) made of implant grade PTFE secured with a commercially 
available polyester suture.  Table 2 provides an overview of the specific tests performed, all of 
which were performed in compliance with FDA Good Laboratory Practice (GLP) regulations 
(21 CFR Part 58).  Summaries of the test methods are provided in Table S2 in the Supporting 
Information. 
All preclinical biostability studies were performed in accordance with the United States 
National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals, which 
includes approval by the test facility Institutional Animal Care and Use Committee (IACUC).  
The test facility was registered with the United States Department of Agriculture (USDA, 
#41-R0074) and accredited by the Association for the Assessment and Accreditation of 
Laboratory Animal Care (AAALAC, aaalac.org). 
 
Toxicological risk assessment from exhaustive extraction and leachables analysis:  
Potential toxicological risks of the Foldax Tria Aortic Valve, including the LP leaflets were 
assessed using exhaustive extraction performed in triplicate with water (polar), 50% 
ethanol/water (semi-polar), and hexane (non-polar) solvents, all at 50 °C for 72 h.  Any 
compounds/elements extracted from the valves were identified by QTOF-GCMS, QTOF-
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LCMS, and ICP-MS.  Relative quantification was performed in triplicate by QTOF-GCMS 
and UHPLC-CAD-UV.  See the Supporting Information for additional analytical method 
details.  Grouping of compounds was performed when consistent toxicological data were 
available.  The total concentration per device for a compound group represented a sum of the 
amounts for each individual compound within a group.  All compounds found with maximum 
levels above the analytical evaluation threshold (AET) of 1.5 µg device-1, a limit supported by 
the ICH M7 guidance, were reported.  A reporting limit of 1.0 µg device-1 was used for ICP-
MS elemental data.  Data from the exhaustive extractions were key inputs in the subsequent 
assessment of toxicological risk using methods consistent with ISO 10993-17:2002 R2008. 
A biologically relevant, simulated-use leachables analysis was also performed in 
triplicate, using both PBS (polar) and 40% ethanol/water (semi-polar) as extraction solvents at 
37 °C for 72 h.  Identification and quantification of compounds was performed in an identical 
manner as the exhaustive extraction described above. 
The toxicological evaluation/risk assessment process for both leachables and exhaustive 
extraction was performed by an experienced toxicologist and followed the general approach 
described in ISO 10993-17:2002 R2008.  The identification and characterization of potential 
deleterious effects of exposure to extractable chemicals/elements included the establishment 
of a tolerable intake, TI [µg kg-1 day-1], for the chemicals/elements and calculation of the 
human dose equivalent, HDE [µg kg-1], and a margin of safety, MOS = TI/HDE.  Due to the 
demonstrated non-mutagenic nature of the Tria heart valve, the default TI used for 
compounds without alternative data was 1.5 µg kg-1 day-1, the Cramer class III Threshold of 
Toxicological Concern (TTC). 
 
Subchronic toxicity (140 day) preclinical evaluation:  Tria aortic valves with LP leaflets 
were evaluated in the healthy ovine model over an implant period of 140 days.  Sterilized 
Foldax Tria valves (23 mm) were implanted in 8 animals (n=8 test samples).  A sterile human 
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Carpentier-Edwards Perimount™ aortic bioprothesis model 2900-25 mm was implanted in 2 
animals as a clinically acceptable, benchmark control device (n=2 controls).   
Animals were screened for compatible annulus size prior to enrollment.  A total of ten (2 
female, 8 male) sheep, 40-60 kg in weight, underwent a left thoracotomy and were prepared 
for cardiopulmonary bypass.  Once on bypass, the aorta was opened and the test or control 
device was implanted as per the manufacturer instructions.  During the procedure, activated 
clotting time was maintained above 250 s by the administration of intravenous heparin, as 
needed.  The aorta was then sutured closed and the animals were weaned off bypass.  No post-
op anticoagulant therapy was administered.  General health and clinical chemistry (CBC, 
serum chemistry, LDH, haptoglobin, free hemoglobin, reticulocyte count, coagulation panel) 
were assessed regularly, beginning at day 7 and monthly thereafter.  At approximately 140 
days post-implant, the animals underwent a sedated terminal procedure and a gross necropsy 
was performed.  The valve, heart and lungs, as well as tissues from the lymph nodes, liver, 
spleen, kidney, and brain were collected for histological evaluation.  All histopathological 
data collected from the Tria aortic valve were compared directly to the control valve. 
This preclinical study was performed in accordance with the NIH Guide for the Care and 
Use of Laboratory Animals, which includes approval by the test facility IACUC.  The test 
facility was registered with the USDA (#41-R0074) and accredited by AAALAC (aaalac.org). 
 
Ex Vivo AV shunt thrombogenicity study:  Six (6) LP grafts (4 mm diameter, 70 mm 
long) were prepared by dip-coating a stainless steel mandrel in a 22% (w/w) LP/DMAc 
solution.  Each sample was dip coated 4 times in a glove box at 85 %RH.  Between each 
coating, samples were rotated in an oven at 55 C for 30 min.  After the final coating, samples 
were held in a 55 C oven overnight.  LP grafts were removed from the mandrels under 
running RO water.  Grafts were packaged and sterilized by ethylene oxide. 
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Silicone rubber tubing (4.0 mm ID, 6.5 mm OD) was abutted to both ends of the grafts 
and bonded with silicone medical adhesive and an overlying 15 mm length of FEP heat shrink 
tubing (Figure 3). 
The ex vivo, nonhuman primate (NHP) AV shunt method previously described by Harker 
and Hanson was employed to evaluate vascular graft thrombogenicity.[38]   A single baboon 
with no history of anticoagulation or antiplatelet therapy was utilized for this study.  Six LP 
grafts were tested over the course of two days.  CBC values and platelet counts were 
confirmed to be normal prior to the start of each study.  A silicone rubber tubing A-V femoral 
shunt was surgically established.  Autologous 111In-labeled platelets and 125I-labeled 
fibrinogen (pooled) were introduced into the subject‟s circulation.   The graft segment was 
primed with isotonic saline and added into the shunt circuit.  Blood flow through the circuit 
was controlled with a single distal clamp and continuously monitored to be ~100 ml min-1.  
Platelet accumulation in the central 20 mm of the graft was measured every three minutes for 
one hour by scintigraphy using a gamma camera.  After the one-hour exposure, the graft 
segment was removed from the shunt circuit and flushed with isotonic saline until all visible 
blood was removed.  The silicone tubing on either side of the LP graft was then removed, and 
the LP graft was stored at 4 °C for 30 days, allowing 111In decay and quantification of 125I-
labelled fibrin/fibrinogen deposits on the central 50 mm of each LP graft with a gamma 
camera. 
Platelet and fibrin deposition on the LP grafts were compared to historical data from 
ePTFE grafts (n=6) of similar size, using t-tests at 15, 30, 45, and 60 min.  A p-value of 0.05 
was considered statistically significant. 
This preclinical study was performed in accordance with the NIH Guide for the Care and 
Use of Laboratory Animals, which includes approval by the test facility IACUC.  The test 
facility was registered with the USDA (#92-R-001) and accredited by AAALAC (aaalac.org). 
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In vivo biostability in a rabbit model:  Pellethane 2363-80A (Lubrizol), Pellethane 2363-
55D (Lubrizol) and LP polymer solutions with 25% (w/w) solids content in DMAc were 
applied to a glass plate using a film casting knife.  DMAc was evaporated in a 55 C oven 
overnight.  LP films were peeled off the glass plates under running RO water.  Final film 
thicknesses were determined to be 0.5-0.7 mm.  Samples were defined as: 
Positive Control:  Pellethane 80A PEU (in vivo degradation well documented)[4,19] 
Negative Control:  Pellethane 55D PEU (strong history of clinical use, acceptable 
biostability) [4,19] 
Test Article:  LP SiPUU 
Dumbbells of 3 cm length with holes in each end were punched from the sheets.  
Polycarbonate stretching mandrels were machined from sheet material.  Dumbbell samples 
and mandrels were sterilized by ethylene oxide. 
Under aseptic conditions, all polymer samples were strained with forceps and mounted 
onto polycarbonate mandrels, placing the sample end holes over the ends of the mandrels 
(Figure 7).  Mandrel dimensions were carefully controlled to result in a 150% strain condition 
in the central, reduced cross section region of the dumbbell.   
Strained samples were aseptically implanted subcutaneously above the dorsal muscle of 
rabbits.  One of each sample type was implanted using random site selection on each side of 
the spine to eliminate position bias (Figure 7).  A total of 8 rabbits and 16 of each sample type 
were implanted.  Post-surgical health checks and wound site observations were performed 
daily.   
Rabbits were euthanized after 12 weeks (n=4) or 24 weeks (n=4), when samples were 
carefully removed from the surrounding tissue.  Samples were stored in normal saline until 
evaluation.   
Previous reports indicate that visual and SEM surface assessments are the most sensitive 
method for detecting PU degradation in this type of study.  Therefore, the surfaces of all 
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explanted samples were first evaluated visually using the scoring scheme as defined by Martin 
et al.[16,44] 
1 = specimen smooth on all surfaces, no cracking observed 
2 = patches of cracking or pitting over less than 10% of surface area 
3 = patches of cracking or pitting over 10-70% of surface area 
4 = fine cracking or pitting over greater than 70% of surface area 
5 = any deep cracking covering less than 70% of surface area 
6 = deep cracking covering more than 70% of surface area and/or specimen breakage.  
Additionally, all explanted samples were evaluated using FE-SEM-EDAX (FEI Quantum 
600) for evidence of degradation, such as pitting and cracking, and calcium deposition. 
The in vivo portion of this biostability study was performed in Australia and approved by 
the Commonwealth Scientific and Industrial Research Organization (CSIRO) North Ryde 
Animal Ethics Committee in accordance with the Australian Code for the Care and Use of 
Animals for Scientific Purposes. 
 
Statistical Analysis:  Continuous variables are expressed as mean ± standard deviation.  
The statistical analysis of ex vivo platelet adhesion and thrombus formation was performed 
between the test and control groups, using a two-sided t-test in Microsoft Excel.  Each group 
at each time point consisted of at least 5 data points.  Data was used as collected, with no pre-
processing.  Significance was defined as p ≤ 0.05. 
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Supporting Information  
Supporting Information is available from the Wiley Online Library or from the author. 
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Figures and Tables 
 
Note that formal figures were submitted separately as individual files.  The figures below are 
included for reviewers‘ reference only. 
 
 
 
 
Figure 1.  Foldax Tria Aortic Valve with LP leaflets.  23 mm outer diameter. 
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Figure 2.  Representative 140 day ovine study explant pathology.  Left: LP Tria valve images.  
Right:  Carpentier-Edwards Perimount control tissue valve images.  Top: Gross images after 
removal of valves and trimming of aortic tissue.  Middle:  Histopathology of frame, leaflet 
and surrounding tissue.  Bottom:  Histopathology of leaflet tips.  All histopathology slides 
were prepared with H&E stain and are shown at a consistent magnification as demonstrated 
by the scale bars.  Note that the LP material does not significantly absorb H&E stain, 
therefore the LP leaflets are difficult to visualize.  The boundary of the LP material has been 
highlighted with a dashed line in the middle-left image. 
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Figure 3.  NHP blood circulating ex vivo through the LP graft (center) bonded to silicone 
rubber AV shunt tubing (left and right). 
 
 
 
 
Figure 4.  Platelet deposition on LifePolymer (LP) and ePTFE reference grafts in the NHP 
AV shunt loop.  Data shown as average with error bars representing one standard deviation.  
P values represent a two-sided t-test performed between the LP test group (n=6) and the 
ePTFE reference group (n=5) at specific time points. 
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Figure 5.  Assessment of degradation by visual examination of LP test article and PU control 
article cast films after 6 months in vivo under 150% strain.  The definitions of each rating are 
provided on the left.  The values shown in this graph represent an overall degradation 
assessment of each group.  
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Positive Control (80A):  Deep cracking, full thickness defects, 
and specimen breakage. 
 
  
Negative Control (55D):  Minor surface pitting and cracking 
was observed on all samples. 
 
  
LP Test Material:  Smooth on all surfaces.  No cracking.   
 
Figure 6.  Representative FE-SEM images of LP test article and PU control article cast films 
after 6 months in vivo under 150% strain. Images depict the center of two representative 
explanted dogbones from each group.  Scale bars = 500 µm.   
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Figure 7.  Rabbit biostability study sample construction and subcutaneous implant locations.  
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Table 1.  SiPUU characterization data compiled from 14 commercial batches of LP. 
Property Analytical 
Tool 
Unit Average StDev 
Mw GPC Da 552,800 87,100 
Mn GPC Da 175,600 21,300 
PDI GPC n/a 3.15 0.31 
Tg (initial heat) DSC C -4.0 1.7 
Tg (cooling) DSC C -7.8 2.5 
Tg (reheat) DSC C -3.6 2.0 
IR Spectrum Correlation 
to Reference 
ATR-FTIR n/a 0.9977 0.0005 
UTS Tensile MPa 38.3 1.8 
Elongation Tensile % 760 43 
Dynamic Modulus Dynamic 
Tester 
MPa 28.7 0.7 
Tear Energy Threshold Dynamic 
Tester 
J m-2 291 73 
 
 
Table 2.  ISO 10993 biocompatibility testing results on Tria valves with LP leaflets. 
Test Description Relevant Std Results 
Cytotoxicity - MEM 
Elution Assay 
ISO 10993-5 Pass, Non-Cytotoxic. 
 
The positive and negative control results met the validity criteria.  At 24, 
48, and 72 hours, no reactivity, cell lysis, or reduction of cell growth was 
observed in the triplicate test article wells.  Therefore, the test article 
received a grade of „0‟ and was considered Non-Cytotoxic. 
Intracutaneous 
Reactivity Test 
ISO 10993-10 Pass, Non-Irritant. 
 
All assay validity criteria were met.  Erythema and edema was not 
observed at any site on any subject at any time point (24 h, 48 h, 72 h) 
for both normal saline extract and sesame seed oil extract.  Therefore the 
test article was considered a non-irritant. 
Acute Systemic 
Toxicity Test 
ISO 10993-11 Pass, No Acute Systemic Toxicity. 
 
All 20 test and control animals remained in overall good health over the 
course of the 72 h study.  None of the animals treated with the test article 
extracts showed a significantly greater reaction than the animals treated 
with the negative controls.  The test article showed no evidence of acute 
systemic toxicity. 
Sensitization - 
Guinea Pig 
Maximization 
ISO 10993-10 Pass, Non-Sensitizer. 
 
All 36 test and control animals remained in overall good health over the 
course of the study.  The overall pattern, intensity, and duration of 
reactions in the saline and sesame seed oil test article groups were 
identical to the negative control group, no erythema or edema observed.  
Based on the results of this study, the test article showed no evidence of 
delayed dermal contact sensitization and was considered a non-sensitizer. 
Pyrogenicity - 
Material Mediated  
ISO 10993-11 Pass, Non-Pyrogen. 
 
None of the 3 rabbits in this study showed a rise in body temperature 
>0.1 C above its control temperature.  Therefore, the test article showed 
no evidence of material mediated pyrogenicity.   
Hemolysis Assay, 
Direct and Extract 
Methods 
ISO 10993-4, 
ASTM F7756-13 
Pass, Non-Hemolytic. 
 
Validity criteria for the positive and negative controls were met.  The test 
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article and test article extracts were determined to produce minimal 
hemolysis, equal to the negative controls.  Therefore, the test articles 
were determined to be non-hemolytic using both direct and extract 
methods. 
Partial 
Thromboplastin 
Time 
ISO 10993-4, 
ASTM F2382 
Pass, Test article performed better than the reference material (HDPE). 
 
The replicate variability of the controls, as well as the reference material, 
met the criteria for a valid assay.  The test article had an average clotting 
time of 110.1 seconds, which was 112% of the negative control, and 
found to be statistically significant (p<0.05).  Therefore, the statistical 
analysis indicates the test article performed better than the reference 
material. 
Complement 
Activation 
ISO 10993-4 Pass, Test article complement activation is lower than the negative 
reference material (HDPE). 
 
Using the SC5b-9 assay, the test article exhibited activation at 6394 ng 
mL-1 and was 0.1% of the normalized SC5b-9 concentration produced by 
the positive control, cobra venom factor (CVF). In comparison, the 
negative reference material (HDPE) exhibited 0.1% activation relative to 
the CVF. The test article results were statistically significantly (p<0.05) 
lower than the negative reference material. 
Genotoxicity - AMES ISO 10993-3 Pass, Non-Mutagenic. 
 
Under the conditions of this study, the mean number of revertant colonies 
for the test article was less than 2-fold over the mean number of revertant 
colonies for the negative control; therefore the test article was considered 
Non-Mutagenic. 
Genotoxicity - Mouse 
Lymphoma 
ISO 10993-3 Pass, Non-Mutagenic and Non-Clastogenic.   
 
The controls for the assay performed as required, qualifying both the 
assay and cell culture system as valid. The mutant frequencies and 
cloning efficiencies of preparations treated with test article were within 
the limits defined for a negative response. Accordingly, the test article is 
considered to be non-mutagenic and non-clastogenic. 
 
 
Table 3. Quantity of leachable and extractable compounds from Tria valves Identified by GC-
MS and LC-MS. 
  Exhaustive Extraction Leachables 
Analysis 
Type 
Compounds 
Identified Water 
50% 
Ethanol/ 
Water Hexane PBS 
40% 
Ethanol/ 
Water 
GC-MS Total  0 24 56 3 8 
Unique  0 11 12 a) 3 6 
Related 
Groups 
0 5 4 0 1 
LC-MS Total  13 b) 91 72 9 109 
Unique  3 b) 8 2 7 17 
Related 
Groups 
4 7 4 1 9 
a) additional two compounds identified in hexane also identified in ethanol/water extract 
b) two of the three compounds were identified by UV detection, not MS detection 
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A siloxane poly(urethane-urea) elastomer recently developed for heart valve leaflets 
demonstrates a robust, scalable synthesis process with minimal variation.  Aggressive testing 
confirms biocompatibility, negligible toxiciological risk from extractable and leachable 
compounds, low thrombogenicity, and excellent biostability.  Ovine implantation of heart 
valves integrating this new elastomer confirms leaflet function and tissue/blood compatibility.  
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